Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Transitional Cell

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

9 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase 1/2 Recruiting

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06356155 2025-07-29

NEPTUNE

32 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Transitional Cell

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05406713 2025-06-10

Pembrolizumab in Muscle-invasive Bladder Cancer

Phase 2 Active not recruiting

46 enrolled

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT02717156 2025-06-05

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

103 enrolled

Carcinoma, Transitional Cell, Prostatic Neoplasms

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03240016 2025-01-16

ABLE

36 enrolled 14 charts

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT04637594 2025-01-15

IMAGINE

3 enrolled

Carcinoma, Transitional Cell

NCT03534804 2024-11-26

PemCab

37 enrolled 27 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03486197 2024-11-20

Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

Phase 2 Terminated

12 enrolled 10 charts

Carcinoma, Transitional Cell

NCT05894447 2024-04-12

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Phase 1 Withdrawn

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Transitional Cell

NCT03590054 2024-03-22

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

35 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ureteral Neoplasms

NCT03511391 2024-01-23

CHEERS

DermatologicGenitourinaryHead & NeckThoracic

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT04187872 2023-12-27

TORCH

Phase 1 Terminated

10 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT06050954 2023-11-09

CARMA

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT02581982 2023-01-10

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

27 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03464734 2022-11-30

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

70 enrolled

Carcinoma, Transitional Cell

NCT02500121 2022-09-30

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

108 enrolled 15 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04179110 2022-02-22

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT03407976 2020-07-15

APPEASE

Phase 1 Terminated

5 enrolled